Contact Us

ABCR-T

Antibody-Based Cell Removal Technology

A platform to make blood transfusions safer for cancer and immunosuppressed patients.

What is ABCR‑Technology?

ABCR‑T is the proprietary and patent protected Antibody-Based Cell Removal Technology of Lindis Blood Care GmbH. It uses a trifunctional antibody to aggregate tumor and/or immune cells, enabling their targeted removal through filtration. 

How does it work?

Targeting

The trifunctional antibody binds to tumor and immune cells in the blood.

Aggregation

Bound cells cluster together, forming larger cell aggregates.

Removal

These aggregates are efficiently removed using standard filtration technologies.

Indication Pipeline

Powered by our ABCR-Technology, Lindis Blood Care is redefining blood safety. Our lead product, CATUVAB®, is entering the market to make autologous transfusions safer, while we continue to explore new indications that address critical needs in oncology and immunotherapy.
Cancer Surgery

INDICATION: Removal of tumor cells from salvaged blood during cancer surgery. Enables safe autologous blood transfusion without irradiation – clinically validated in the REMOVE study.

STATUS: CE Certification process

Immunosuppressed Patients

INDICATION: Removal of tumor and immune cells from donor blood for immunosuppressed patients.
Improves transfusion safety in vulnerable patients and opens new options for prophylactic applications.

STATUS: research / non clinical

Expanding Horizons

INDICATION: Expansion of ABCR Technology to new therapeutic areas. Research is ongoing to explore further applications in oncology and beyond.

STATUS: Research

Learn more about CATUVAB

Next target indication for a product based on ABCR-Technology: Immunosuppressed Patients.

CATUVAB® applications can be expanded to the removal of potentially present tumor cells and T cells from donor blood immediately before infusion to immunosuppressed patients.
Immunosuppressed Patient Population:
24mio patients
Patients with immuno­suppressing conditions
  • Hematological malignancies
  • HIV/AIDS
  • Other immune conditions
65mio patients
Patients treated with immuno­suppressive medication
  • Solid malgnancies
  • Organ transplants
  • Other conditions requiring chemotherapy or an immune modulator
  • Within the immunosuppressed patient population, cancer patients, organ transplant patients and patients receiving chemotherapy who regularly suffer from anemia, are the groups who would benefit most from CATUVAB®.
  • Leukemia patients in particular, are given large amounts of donor blood (up to 6 erythrocyte concentrates (ECs)) repeatedly throughout their course of treatment.

Next target indication:

Immunosuppressed Patients

CATUVAB®’s applications can be expanded to the removal of potentially present tumor cells and T cells from donor blood immediately before infusion to immunosuppressed patients.
CATUVAB® is able to address 3 major pain points of allogenic blood transfusion for immunosuppressed patients:
  • Risk of transfusing undetected cancer cells in donor erythrocyte concentrate (esp. In blood from older donors >50y)
  • T cells & NK cells from donor erythrocyte concentrate, enhancing the risk for Graft versus Host Disease (GvHD) and immunosuppression.
  • Loss of radiated blood due to shortened shelf life of ECs.
  • Immediate availability in urgent cases in hospitals with no immediate access to radiated blood.
  • Up to 3-4 blood bags can be sampled in reservoir of an IBS before using CATUVAB®.
  • No radiation used in removing tumor cells or lymphocytes leads to better shape of red blood cells.
  • Cancer Stem Cells were found to be resistant against radioactive radiation > CSC’s will be removed by CATUVAB®.

Interested in applying CATUVAB®?

Reach out to explore clinical integration or request a direct exchange with our scientific and medical leadership.
Get started